Undifferentiated sinonasal carcinoma may respond to single-fraction boron neutron capture therapy

  • Mauri Kouri*
  • , Leena Kankaanranta
  • , Tiina Seppälä
  • , Leena Tervo
  • , Merja Rasilainen
  • , Heikki Minn
  • , Olli Eskola
  • , Jyrki Vähätalo
  • , Anders Paetau
  • , Sauli Savolainen
  • , Iiro Auterinen
  • , Juha Jääskeläinen
  • , Heikki Joensuu
  • *Corresponding author for this work

    Research output: Contribution to journalArticleScientificpeer-review

    Abstract

    A large, rapidly progressing, unresectable undifferentiated sinonasal head and neck carcinoma regressed rapidly following single fraction boron neutron capture therapy (BNCT). The main toxicity consisted of mucositis lasting for a few days. The quality of life improved and was excellent until tumour recurrence 6 months after the date of BNCT.
    Original languageEnglish
    Pages (from-to)83-85
    JournalRadiotherapy and Oncology
    Volume72
    Issue number1
    DOIs
    Publication statusPublished - 2004
    MoE publication typeA1 Journal article-refereed

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • boron neutron capture therapy
    • head and neck carcinoma
    • sinonasal carcinoma
    • boronophenylalanine
    • positron emission tomography

    Fingerprint

    Dive into the research topics of 'Undifferentiated sinonasal carcinoma may respond to single-fraction boron neutron capture therapy'. Together they form a unique fingerprint.

    Cite this